Most Read Articles
28 May 2019
Trifarotene is safe, well-tolerated and effective in treating both facial and truncal acne, according to two phase III trials.
08 May 2019
Antinuclear antibody (ANA) negativity appears to increase the likelihood of developing malignancy in patients with adult-onset dermatomyositis (DM) within 3 years of diagnosis of their DM, according to a recent study.
20 May 2019
Three treatments of ablative fractional CO2 laser (AFCO2L) yield improvements in burn scar pain, itch and dermal architecture 6 weeks after treatment, a recent study has found.
11 Apr 2019
Immune checkpoint inhibitor therapy may lead to various inflammatory reactions with differing degrees of severity, suggests a recent study. Most rashes respond to topical treatment, but immunotherapy is often interrupted by immunobullous and exfoliative presentations.

Secukinumab cardioprotective in patients with plaque psoriasis

25 Dec 2018

Treatment with secukinumab results in improved endothelial function in patients with plaque psoriasis, with the improvements translating to reduced risk of cardiovascular (CV) disease, according to data from the CARIMA trial.

The 52-week, randomized, double-blind, placebo-controlled exploratory trial randomized patients with moderate-to-severe plaque psoriasis without clinical CV disease to receive secukinumab at 300 or 150 mg until week 52, or placebo until week 12 then 300 or 150 mg secukinumab until week 52. The primary outcome of endothelial function was measured using flow-mediated dilation (FMD).

At baseline, FMD was significantly lower in psoriasis patients vs healthy volunteers (4.4 percent vs 6.1 percent; p=0.01). At week 12, FMD increased by 1.2 percent in the 300-mg secukinumab group, by 0.76 percent in the 150-mg group, although these improvements did not reach significance vs the placebo group (p=0.223 and p=0.403 by ANCOVA, respectively).

However, at week 52, FMD further increased across groups. Compared with baseline, week-52 FMD improved significantly in patients receiving the 300-mg secukinumab (increase of 2.1 percent from baseline; 95 percent CI, 0.8–3.3; p=0.0022). Other relevant CV markers showed no change.

Psoriasis is associated with CV diseases and associated risk factors, conferring an approximately 25-percent increase in the risk of CV disease, independent of smoking, obesity and hyperlipidaemia. For optimal patient management and reduction of the overall burden of CVD in psoriasis, dermatologists should be educated about the benefits of appropriate screening and referral for CV risk factors. This is in line with guidelines stating that patients with psoriasis should be screened for traditional, modifiable CV risk factors and managed appropriately to reduce risk. [J Am Acad Dermatol 2018;79:345-352]

IL-17A inhibitors, such as secukinumab, are a new class of anti-inflammatory agents and have been shown to be effective against moderate-to-severe psoriasis.  Inflammatory mechanisms, including the IL-17A pathway, are potential links between psoriasis and CVD. The CARIMA trial indicates that secukinumab exerts a beneficial effect on CV risk in plaque psoriasis patients by improving endothelial function.

Editor's Recommendations
Most Read Articles
28 May 2019
Trifarotene is safe, well-tolerated and effective in treating both facial and truncal acne, according to two phase III trials.
08 May 2019
Antinuclear antibody (ANA) negativity appears to increase the likelihood of developing malignancy in patients with adult-onset dermatomyositis (DM) within 3 years of diagnosis of their DM, according to a recent study.
20 May 2019
Three treatments of ablative fractional CO2 laser (AFCO2L) yield improvements in burn scar pain, itch and dermal architecture 6 weeks after treatment, a recent study has found.
11 Apr 2019
Immune checkpoint inhibitor therapy may lead to various inflammatory reactions with differing degrees of severity, suggests a recent study. Most rashes respond to topical treatment, but immunotherapy is often interrupted by immunobullous and exfoliative presentations.